A comprehensive view of vaccination/immunization. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Catalent and Moderna to extend, expand manufacturing partnership; Catalent to continue Moderna COVID-19 programs, may extend partnership for flu, RSV vaccines, starting at Bloomington, Indiana, facility then expanding to Anagni, Italy, plant

Commentary: Drug companies that made billions from pandemic could see those sales fall by two-thirds globally in 2023 due to built-up product inventories; population immunity from vaccination, past infections means demand for treatments could dip as well

Moderna signs new agreement to use the Personalis NeXT Platform in clinical studies of mRNA-4157/V940, a personalized cancer vaccine jointly developed with Merck; platform will sequence patient genomic information to identify unique genetic mutations

Executive Perspective: Pfizer CEO states 2023 pipeline may have the largest number of new product and indication launches they’ve ever had; Pfizer expects to introduce 19 new products or indications to the market in next 18 months

FDA to convene advisors to review experimental RSV vaccine candidate from Pfizer on February 28; group to meet in March to reviews RSV vaccine candidate from GSK

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count